Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year

Diagnosis and management of acute ischaemic stroke

Thrombolytic Therapy in Stroke: Ischemic Stroke and Neurologic Deficits, Clinical Trials, Thrombolysis Guidelines

Acute Ischemic Stroke and Long-Term Outcome After Thrombolysis

Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke

Use of tPA for the Management of Acute Ischemic Stroke in the ED: ACEP Policy

– Emergency Medicine EducationThrombolytic Use for STEMI: What ED Clinicians Should Know - - Emergency Medicine Education

IJERPH, Free Full-Text

Frontiers Factors associated with functional disability in patients with acute stroke excluded from alteplase administration due to minor non-disabling neurological deficits

Full article: Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase

Tissue Plasminogen Activator for Acute Ischemic Stroke (Alteplase, Activase®)

The Neurotoxicity of Tissue Plasminogen Activator? - Jaspreet Kaur, Zonghang Zhao, Gary M. Klein, Eng H. Lo, Alastair M. Buchan, 2004